3-23 | Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike. In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s priorities over the next ten years. Where are we in the fight against TB? We’re not exactly winning.
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
12-18 | Gilead recently launched one of these drugs for $100/pill in China Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application for the combination of two crucial oral hepatitis C medicines, sofosbuvir and velpatasvir. This combination is the first direct-acting antiviral (DAA) treatment to be registered for use against all genotypes* of the disease.
10-31 | Dramatic price drops should allow countries to provide treatment for millions of people On the eve of the World Hepatitis Summit in Sao Paolo, the international medical humanitarian organization Médecins Sans Frontières (MSF) today announced that it had secured deals for generic hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week treatment course for the two key medicines sofosbuvir and daclatasvir. In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000 per pil
8-22 | Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that safeguards both children and adults from pneumonia was dealt a major blow after the Indian patent office granted a patent to the US pharmaceutical corporation Pfizer for its PCV13 product, marketed as Prevnar13. “It’s unfair and unacceptable that almost a million children die each year from pneumonia, even though a life-saving vaccine is available.
7-25 | Global attention needed to prevent and treat AIDS in antiretroviral era, with 50% of hospital admissions in MSF hospitals already on treatment and showing clinical signs of failure. An unacceptably high number of people continue to develop and die of AIDS1-related diseases across sub-Saharan Africa.